GENinCode
GENinCode is a clinical-stage diagnostics company developing polygenic risk assessment tests for cardiovascular disease and ovarian cancer.
Its portfolio includes CE-marked molecular tests for coronary artery disease, familial hypercholesterolaemia and thrombosis risk, alongside the ROCA test for ovarian cancer surveillance in women with BRCA gene mutations.
Tests combine molecular genotyping with clinical algorithms to generate personalised patient risk scores, supporting clinicians in preventative care and treatment decisions.
Latest News
GENinCode Cuts 2026 Revenue Outlook to About £3.2M, Cash Runway to Q1 2027
GENinCode now expects full-year 2026 revenue of about £3.2 million after H1 revenue fell to £1.1 million from £1.6 million, citing weaker NHS sales and slower uptake through Thermo Fisher Scientific. Cash stood at £2.0 million at the end of June, which the company says extends its runway into Q1 2027.
GENinCode Shares Rise on Positive Coronary Risk Test Data at ESC Congress
GENinCode's shares rose as much as 23% after an independent study presented at the ESC Congress 2026 showed its CARDIO inCode-Score test reclassified coronary risk in 42.6% of patients tested. The polygenic risk score is designed to improve prediction of coronary artery disease beyond standard clinical risk factors.